RecruitingNCT07231835

Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons

RECORD-DCB: Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons


Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment

3,000 participants

Start Date

Nov 11, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The primary aim of this registry is to systematically collect and analyze real-world data on all patients undergoing PCI with the Protégé paclitaxel-eluting DCB to evaluate procedural outcomes, long-term efficacy, and safety across various clinical indications. This registry aims to assess the clinical effectiveness of DCB therapy across diverse patient populations, including those with stable coronary artery disease (CAD) and acute coronary syndromes (ACS), as well as various lesion subsets, encompassing (but not limited to) in-stent restenosis (ISR), de novo coronary lesions, small vessel disease, bifurcation and calcified lesions, coronary bypass graft lesions, and patients at high risk of bleeding. Additionally, the study aims to identify predictors of success, complications, and optimal treatment strategies to further refine the use of DCBs.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients undergoing PCI with the Protégé paclitaxel-eluting DCB
  • Age ≥ 18 years
  • Presence of a de novo lesion or in-stent restenosis in a native coronary artery or a in a bypass graft and suitable for PCI
  • Reference vessel diameter between 2.0 - 4.5 mm
  • Patient suitable for dual antiplatelet therapy (DAPT)

Exclusion Criteria2

  • Inability to provide informed consent
  • Allergy to paclitaxel

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Amsterdam UMC

Amsterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07231835


Related Trials